scholarly journals Comparison of current UICC-TNM classification and new AJCC-TNM classification for malignant melanoma: Analysis on 342 Japanese patients.

Skin Cancer ◽  
2002 ◽  
Vol 17 (1) ◽  
pp. 38-43
Author(s):  
Sachiko NORO ◽  
Akifumi YAMAMOTO ◽  
Naoya YAMAZAKI ◽  
Hideki MACHIDA ◽  
Yoriko YAMAZAKI ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Tnm Classification ◽  
Japanese Patients

scholarly journals Comparison of the previous UICC-TNM classification (1997) and new UICC-TNM classification (2002) for malignant melanoma: Analysis of 342 Japanese patients

Skin Cancer ◽  
2003 ◽  
Vol 18 (2) ◽  
pp. 214-220 ◽  
Author(s):  
Sachiko NORO ◽  
Akifurni YAMAMOTO ◽  
Naoya YAMAZAKI ◽  
Yoriko YAMAZAKI ◽  
Hisashi UHARA ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Tnm Classification ◽  
Japanese Patients

Risk Classification of Human Papillomavirus-related Oropharyngeal Squamous Cell Carcinoma in Japanese Patients

2021 ◽  
Author(s):  
Jun ITAMI ◽  
Kenya KOBAYASHI ◽  
Taisuke MORI ◽  
Yoshitaka HONMA ◽  
Yuko KUBO ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Human Papillomavirus ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Tnm Classification ◽  
Survival Rates ◽  
Japanese Patients ◽  
Risk Classification ◽  
Oropharyngeal Squamous Cell Carcinoma ◽  
Neck Node

Abstract Purpose The validity of the risk classification according to Ang for human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) remains to be studied in patients treated by methods other than chemoradiotherapy and in Japanese patients. In this study, the validity of Ang's risk classification was studied in Japanese patients treated using various methods, including surgery.Material and Method Between 2010 and 2018, 122 patients with HPV-related OPSCC stages III and IV according to the TNM classification 7th edition (TNM-7) were treated curatively at a single institution in Japan. The median age was 62.7 years. Sixty-seven patients (54.9%) were classified as stage I according to the TNM 8th edition (TNM-8). Over 50% of the patients underwent surgery with or without adjuvant therapy. The influence of multiple factors on survival was determined.Results Age, amount of smoking, secondary cancer, and N-stage according to the TNM-7 significantly influenced survival. Ang's risk classification was also predictive of prognosis, but if 30 pack-years (PYs) instead of 10 PYs is employed to dichotomize the amount of smoking, the new risk classification can significantly better predict prognosis. According to the new risk classification, favorable and unfavorable risk patients showed 5-year progression-free survival, disease-specific survival, and overall survival rates of 72.7% and 35.9%, 94.6% and 76.2%, and 92.6% and 62.7%, respectively.Conclusions Even in patients treated by methods other than chemoradiotherapy and in Japanese patients, the combination of the amount of smoking and neck node status is useful in prognosis prediction.

scholarly journals Lacrimal Sac Malignant Melanoma in 15 Japanese Patients: Case Report and Literature Review

2019 ◽  
Vol 7 ◽  
pp. 232470961988805 ◽  
Author(s):  
Toshihiko Matsuo ◽  
Takehiro Tanaka ◽  
Osamu Yamasaki
Keyword(s):  
Malignant Melanoma ◽  
Local Recurrence ◽  
Braf Inhibitor ◽  
Japanese Patients ◽  
The Body ◽  
Braf V600e ◽  
Lacrimal Sac ◽  
Diffuse Infiltration ◽  
Uptake Sites ◽  
Abnormal Uptake

Background. Primary malignant melanoma of the lacrimal sac is rare. A patient with lacrimal sac melanoma was presented, and 14 Japanese patients with lacrimal sac melanoma in the literature were reviewed. Case Presentation. A 78-year-old Japanese man was presented with painless swelling of the lacrimal sac on the left side. Dacryocystectomy revealed diffuse infiltration with large epithelioid cells, sometimes with pigments, which were positive for cocktail mix of antibodies to tyrosinase, melan A (MART-1), and HMB45, leading to pathological diagnosis of melanoma. One month later, positron emission tomography (PET) revealed 2 high-uptake sites (SUVmax = 10.29 and 15.38) at the levels of medial canthus and nasolacrimal duct, but no abnormal uptake in the other site of the body. The lesion had the BRAF V600E mutation. He began to take daily oral dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor), leading to no abnormal uptake on PET in half a year. He had stable disease in good physical status with small and weak uptake sites of lymph nodes on PET 1 year later. Results. In the review of 15 Japanese patients, including this patient, local recurrence was noted in 4 patients, regional lymph node metastasis only in 3, distant metastasis in 6, and no metastasis in 6. Five patients died within 2 years and the others were alive in short follow-up periods. Conclusions. Chemotherapy was the standard for local recurrence or metastasis. Emerging molecular target drugs, as shown in the present patient, would change the strategy for management of lacrimal sac melanoma.

scholarly journals Phase I study of pegylated interferon‐alpha‐2b as an adjuvant therapy in Japanese patients with malignant melanoma

2016 ◽  
Vol 43 (10) ◽  
pp. 1146-1153 ◽  
Author(s):  
Naoya Yamazaki ◽  
Hisashi Uhara ◽  
Hidefumi Wada ◽  
Kenji Matsuda ◽  
Keiko Yamamoto ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Adjuvant Therapy ◽  
Phase I ◽  
Interferon Alpha ◽  
Phase I Study ◽  
Japanese Patients ◽  
Pegylated Interferon ◽  
Pegylated Interferon Alpha ◽  
Interferon Alpha 2B

Clinical features of anorectal malignant melanoma in the Japanese patients

1998 ◽  
Vol 114 ◽  
pp. A692
Author(s):  
Y. Tsubosa ◽  
T. Akasu ◽  
H. Miyake ◽  
Y. Moriya ◽  
S. Fujita ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Clinical Features ◽  
Japanese Patients ◽  
Anorectal Malignant Melanoma

scholarly journals Five‐year survival with nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma

2021 ◽  
Author(s):  
Hisashi Uhara ◽  
Yoshio Kiyohara ◽  
Jiro Uehara ◽  
Yasuhiro Fujisawa ◽  
Tatsuya Takenouchi ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Japanese Patients

Safety and efficacy of nivolumab in Japanese patients with malignant melanoma: An interim analysis of a postmarketing surveillance

2018 ◽  
Vol 45 (4) ◽  
pp. 408-415 ◽  
Author(s):  
Yoshio Kiyohara ◽  
Hisashi Uhara ◽  
Yoshihiko Ito ◽  
Noritake Matsumoto ◽  
Tetsuya Tsuchida ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Interim Analysis ◽  
Japanese Patients ◽  
Postmarketing Surveillance ◽  
Safety And Efficacy

scholarly journals Long‐term follow up of nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma

2019 ◽  
Vol 110 (6) ◽  
pp. 1995-2003 ◽  
Author(s):  
Naoya Yamazaki ◽  
Yoshio Kiyohara ◽  
Hisashi Uhara ◽  
Jiro Uehara ◽  
Yasuhiro Fujisawa ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Japanese Patients ◽  
Long Term Follow Up
Sign in / Sign up

Export Citation Format

Share Document